Use of the novel INNO-LiPA line probe assay for detection of hepatitis B virus variants that confer resistance to entecavir therapy

J Clin Microbiol. 2009 Feb;47(2):485-8. doi: 10.1128/JCM.01678-08. Epub 2008 Dec 3.

Abstract

A line probe assay (INNO-LiPA DR, version 3) for the detection of hepatitis B virus mutations that confer resistance to entecavir therapy was evaluated. The INNO-LiPA DR assay is a highly sensitive assay that is easily applicable for the detection and monitoring of entecavir resistance-conferring mutations and is more sensitive than sequencing for the detection of mixed sequences.

Publication types

  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / pharmacology*
  • DNA, Viral / genetics
  • Genotype
  • Guanine / analogs & derivatives*
  • Guanine / pharmacology
  • Hepatitis B virus / drug effects
  • Hepatitis B virus / genetics*
  • Hepatitis B virus / isolation & purification*
  • Humans
  • Molecular Diagnostic Techniques / methods*
  • Mutation, Missense
  • Nucleic Acid Hybridization / methods*
  • Sensitivity and Specificity

Substances

  • Antiviral Agents
  • DNA, Viral
  • entecavir
  • Guanine